GRI Bio News

Actualités Eulerpool GRI Bio

Actualités de l'action GRI Bio

GRI Bio est suivi par de nombreux journalistes et investisseurs dans le monde. Nous rassemblons ici les dernières actualités concernant GRI Bio.

• 28 janvier·

  Benzinga
  GRI Bio shares are trading higher after the company announced data from its recently completed Phase 2a clinical study of GRI-0621 in Idiopathic Pulmonary Fibrosis
• 23 janvier·

  Benzinga
  Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
• 20 janvier·

  Benzinga
  12 Health Care Stocks Moving In Tuesday's After-Market Session
• 8 janvier·

  Benzinga
  12 Health Care Stocks Moving In Thursday's After-Market Session
• 8 janvier·

  Benzinga
  GRI Bio Announced Cytometry Data From Phase 2a GRI-0621-IPF-02 Clinical Trial Evaluating GRI-0621 For Treatment Of Idiopathic Pulmonary Fibrosis
• 11 décembre·

  Yahoo
  GRI Bio Announces Pricing of $8,000,000 Million Public Offering
• 11 décembre·

  Benzinga
  GRI Bio Drug Shows Promising Lung Function Recovery In Patients With Thickened Lungs
• 10 décembre·

  Yahoo
  GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
• 10 décembre·

  Benzinga
  GRI Bio shares are trading higher after the company announced topline data from the Phase 2a GRI-0621-IPF-02 clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis met its primary and secondary endpoints.
• 8 décembre·

  Benzinga
  12 Health Care Stocks Moving In Monday's Intraday Session
• 8 décembre·

  Benzinga
  Gri Bio Phase 2a Trial For Idiopathic Pulmonary Fibrosis Met Primary Endpoint & Certain Secondary Endpoints
• 8 décembre·

  Benzinga
  GRI Bio's GRI-0621 Meets Primary Endpoint In Phase 2a IPF Trial, Showing Improved FVC, Biomarker Evidence Of Anti-Fibrotic Activity And Strong Safety Profile
• 14 août·

  Benzinga
  GRI Bio Q2 EPS $(1.31), Inline
• 31 juillet·

  Yahoo
  GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment
• 31 juillet·

  Benzinga
  Nasdaq Surges Over 1%; Microsoft Posts Upbeat Earnings
• 1 juillet·

  Yahoo
  GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
• 1 juillet·

  Benzinga
  GRI Bio Completes Enrollment In Phase 2a Trial Of GRI-0621 For Idiopathic Pulmonary Fibrosis; 2- And 6- Week Interim Safety Results Demonstrated GRI-0621 To Be Safe And Well-Tolerated In The First 12 And 24 Patients Evaluated, Respectively
• 26 juin·

  Yahoo
  GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
• 21 mai·

  Yahoo
  GRI Bio to Participate in the Virtual Investor Closing Bell Series
• 16 mai·

  Yahoo
  GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

Communiqués de presse relatifs à l'action GRI Bio

GRI Bio publie régulièrement sur son site web des communiqués pertinents pour les investisseurs.